Linked Life Data

20228410

Source:http://linkedlifedata.com/resource/pubmed/id/20228410

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-3-15
pubmed:abstractText
Pre-operative treatment with recombinant human erythropoietin may improve aortic stenosis patients' condition, including anemia and/or cardiac dysfunction, for subjecting to aortic valve replacement. In this study, we tested this hypothesis in a mouse model of aortic stenosis. Adult male mice were subjected to either aortic stenosis created by aortic ligature or sham operation. Aortic stenosis for 4 weeks caused cardiac hypertrophy, pulmonary congestion and left ventricular dysfunction. It was associated with increased levels of tumor necrosis factor-alpha in serum and myocardium, and reduced levels of interleukin-10 in myocardium but not in serum. Myocyte apoptosis rate, level of cleaved caspase 3, activity of nuclear factor-kappaB and expression of p38-MAPK pathway were also elevated. Erythropoietin treatment increased hematocrit but did not prevent the development of cardiac hypertrophy. It, however, reduced the apoptosis, prevented the increases in tumor necrosis factor-alpha, nuclear factor-kappaB activation and phosphorylation of p38, and attenuated the increases in lung weight, the decreases in LVEF and LVFS, and the increases in LVDd and LVDs. In conclusion recombinant human erythropoietin has cardioprotective effects in maladaptive cardiac hypertrophy by inhibiting nuclear factor-kappaB activation, phosphorylation of p38-MAPK pathway, and production of tumor necrosis factor-alpha, together leading to a reduced apoptosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1899-1505
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
13-20
pubmed:meshHeading
pubmed-meshheading:20228410-Animals, pubmed-meshheading:20228410-Aortic Valve Stenosis, pubmed-meshheading:20228410-Apoptosis, pubmed-meshheading:20228410-Apoptosis Regulatory Proteins, pubmed-meshheading:20228410-Cardiomegaly, pubmed-meshheading:20228410-Cardiotonic Agents, pubmed-meshheading:20228410-Disease Models, Animal, pubmed-meshheading:20228410-Erythropoietin, pubmed-meshheading:20228410-Ligation, pubmed-meshheading:20228410-MAP Kinase Signaling System, pubmed-meshheading:20228410-Male, pubmed-meshheading:20228410-Mice, pubmed-meshheading:20228410-Mice, Inbred C57BL, pubmed-meshheading:20228410-NF-kappa B, pubmed-meshheading:20228410-Phosphorylation, pubmed-meshheading:20228410-Recombinant Proteins, pubmed-meshheading:20228410-Tumor Necrosis Factor-alpha, pubmed-meshheading:20228410-p38 Mitogen-Activated Protein Kinases
pubmed:year
2010
pubmed:articleTitle
Cardioprotection of exogenous erythropoietin in mice with ligature-induced aortic stenosis: effects on maladaptive cardiac hypertrophy.
pubmed:affiliation
Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't